• SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Mankind Pharma Q1 PAT jumps 10% YoY to ₹ 536 cr 
(15:41, 31 Jul 2024)
Revenue from operations stood at ₹ 2,893.42 crore in Q1 FY25, up 12.20% as against with ₹ 2,578.62 crore in Q1 FY24.

Profit before tax was at ₹ 667.62 crore in Q1 FY25, registering a growth of 9.89% from ₹ 624.47 crore recorded in Q1 FY24.

EBITDA grew 4% to ₹ 686 crore in the June 2024 quarter from ₹ 660 crore posted in Q1 FY24. EBITDA margin reduced to 23.7% in Q1 FY25 as compared to 25.6% recorded in the corresponding quarter previous year.

Domestic revenue stood at ₹ 2,634 crore in Q1 FY25, up by 8.9% YoY as compared with ₹ 2,419 crore posted in Q1 FY24. While, export revenue stood at ₹ 259 crore, up by 61.9% YoY as compared with ₹ 160 crore posted in the same quarter of the previous year.

Export growth driven by increase in its base business, and new launches. During the quarter, the company has launched 2 new products in US taking the total launched products to 41.

Cash flow from operations stood at ₹ 546 crore in Q1 FY25.

On standalone basis, the company's net profit jumped 25.46% to ₹ 513.49 crore in Q1 FY25 as against with ₹ 409.28 crore posted in Q1 FY24. Revenue from operations stood at ₹ 2,403.26 crore in the June quarter 2024, up 14.86% year on year.

Rajeev Juneja, vice chairman & managing director, Mankind Pharma, said, We Witnessed a steady revenue growth of 12.2% YoY with continued outperformance of 1.2x to IPM driven by a strong recovery in volume with Adjusted EBITDA margins of 25.2%. We are now the 2nd largest pharma company by volume with an increase in market share of 20 bps YoY to 6.1%.

Consistently expanding from mass market to specialty chronic leading to outperformance of 1.3x to IPM Chronic (with chronic share - 37%). BSV's2 super specialty business with high entry barrier portfolio and complex R&D tech platform to add another layer of growth. In this quarter we In-licensed Inclisiran (Cardiac - lipid lowering) from Novartis, and Vonoprazan (Gastro) from Takeda.

Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.

Shares of Mankind Pharma fell 1.02% to ₹ 2,035 on the BSE.

Powered by Capital Market - Live News

No Details of this news available

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.